Evogene Stock

Evogene EBIT

Delisted

The EBIT of Evogene (EVGN) as of Jul 26, 2026 is -21.67 M USD. In the previous year, EBIT was -26.52 M USD — a change of -18.32% (higher).

EBIT

-21.67 MUSD

YoY

-18.32%

Last updated:

In 2026, Evogene's EBIT was -21.67 M USD, a -18.32% increase from the -26.52 M USD EBIT recorded in the previous year.

The Evogene EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT (k USD)
Date
EBIT (k USD)
Jan 1, 2020
-24,810.00 base
Jan 1, 2021
-30,860.00 base
Jan 1, 2022
-30,320.00 base
Jan 1, 2023
-26,524.00 base
Jan 1, 2024
-21,665.00 base
Jan 1, 2025 (e)
-12,886.68 base
Jan 1, 2026 (e)
-10,990.50 base
Jan 1, 2027 (e)
-11,296.50 base
YEAREBIT (k USD)
2027 est -11,296.50
2026 est -10,990.50
2025 est -12,886.68
2024 -21,665.00
2023 -26,524.00
2022 -30,320.00
2021 -30,860.00
2020 -24,810.00
2019 -21,040.00
2018 -19,920.00
2017 -21,910.00
2016 -21,070.00
2015 -17,860.00
2014 -15,210.00
2013 -8,630.00
2012 -3,160.00
2011 -3,080.00
2010 -1,980.00
2009 320.00
2008 -4,410.00
2007 -3,910.00
Access this data via the Eulerpool API

Evogene Revenue

Evogene Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2020
1.04 M USD
-24.81 M USD
-23.37 M USD
Jan 1, 2021
930,000.00 USD
-30.86 M USD
-27.79 M USD
Jan 1, 2022
1.68 M USD
-30.32 M USD
-26.64 M USD
Jan 1, 2023
5.64 M USD
-26.52 M USD
-23.88 M USD
Jan 1, 2024
8.51 M USD
-21.67 M USD
-16.49 M USD
Jan 1, 2025 (e)
3.99 M USD
-12.89 M USD
-5.51 M USD
Jan 1, 2026 (e)
2.19 M USD
-10.99 M USD
-12.01 M USD
Jan 1, 2027 (e)
3.72 M USD
-11.30 M USD
-8.89 M USD

Evogene Margins

Evogene stock margins

The Evogene margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Evogene. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Evogene.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2020
45.19 %
-2,385.58 %
-2,247.12 %
Jan 1, 2021
-596.77 %
-3,318.28 %
-2,988.17 %
Jan 1, 2022
-282.74 %
-1,804.76 %
-1,585.71 %
Jan 1, 2023
-42.57 %
-470.28 %
-423.39 %
Jan 1, 2024
19.69 %
-254.55 %
-193.69 %
Jan 1, 2025 (e)
19.69 %
-322.73 %
-138.10 %
Jan 1, 2026 (e)
19.69 %
-501.16 %
-547.53 %
Jan 1, 2027 (e)
19.69 %
-303.42 %
-238.90 %

Evogene Stock analysis

What does Evogene do? Evogene Ltd is an Israeli biotechnology company that focuses on the application of computational biology and genomics to agriculture and biology. The company originated from a spin-off of the Weizmann Institute of Science and was founded in 2002. Today, it is a leading global provider of biotechnology solutions for the agriculture and biotechnology industry. Evogene's business model is based on providing innovative technologies and services for its customers, aiming to improve plant development, particularly in terms of resistance to environmental stress factors and pests. To achieve this, the company utilizes modern biotechnology methods and leverages artificial intelligence. It employs advanced machine learning and large-scale data analysis techniques to gain a better understanding of underlying biological processes. Evogene operates in three core areas: agricultural biotechnology, drug discovery biotechnology, and biomaterials. The company is capable of offering customized biological solutions tailored to the specific needs of its customers. Agricultural biotechnology is one of Evogene's key sectors. It utilizes state-of-the-art technologies and methods to generate plant resistance to pests and environmental factors. With the help of a reliable pipeline of innovative products such as seeds, biostimulants, and fertilizers, Evogene aims to play an important role in food security, environmental sustainability, and resilience to climate change. The company has a strong product pipeline aimed at improving nutrient efficiency of crops while reducing environmental impact from pesticide and fertilizer use. One such product resulting from this pipeline is EvoCanna, which utilizes modern genomics methods to optimize hemp plants in terms of phytocannabinoid biosynthesis. The goal of Evogene's drug discovery biotechnology and biomaterials sector is to develop innovative and effective medicines for diseases such as cancer and obesity. The company utilizes modern machine learning and large-scale data analysis methods to identify the potential of new drug candidates. In the biomaterials sector, Evogene aims to develop innovative technologies and solutions for better and more sustainable use of natural resources. An important application of this concept is biostimulants, which can improve the growth rate, stress tolerance, and yield of crops. Additionally, the company can offer new materials and environmentally friendly solutions in the packaging industry. Overall, Evogene has achieved impressive success in recent years and established itself as a leading biotechnology company. By utilizing cutting-edge technologies, methods, and scientific concepts, particularly artificial intelligence and machine learning, and by operating as a responsible company in the fields of agriculture, biomaterials, and programming, Evogene is able to offer innovative biotechnological solutions. The company is currently well-equipped and has a promising pipeline of groundbreaking innovation projects that embody the desire for a sustainable worldview. Evogene is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing Evogene's EBIT

Evogene's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Evogene's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Evogene's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Evogene’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Evogene stock

EBIT of Evogene is -21.67 M USD in 2026.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

Income Statement — Evogene

All Key Metrics — Evogene